Rui-Cheng Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui-Cheng Wu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Dechao Feng
Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
4 shared publications - Deng-Xiong Li
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China
2 shared publications - Qing-Xin Yu
Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo City, Zhejiang Province, 315211, China
2 shared publications - Wuran Wei
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Akira Miyamoto
Department of Rehabilitation, West Kyushu University, Japan
1 shared publication- Akira Miyamoto
Department of Rehabilitation, West Kyushu University, Fukuoka, Japan
1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (3) , 1-16
A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer
Background: There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. Method: Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. Results: TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. Conclusion: TGM1 has the potential to serve as both a prognostic marker and a drug target.
- 12 March 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (3) , 1-16
Open AccessA pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer
Background: There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. Method: Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. Results: TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. Conclusion: TGM1 has the potential to serve as both a prognostic marker and a drug target.
- 28 February 2024
- Published by Elsevier in Phytomedicine
- Vol. 127, 155503
Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential
- 28 February 2024
- Published by Elsevier in Phytomedicine
- Vol. 127, 155503
Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential
- Open Access
- 6 October 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (1) , 617-618
Auxiliary use of ChatGPT in surgical diagnosis and treatment – correspondence
An abstract is unavailable. This article is available as a PDF only.
- 6 October 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (1) , 617-618
Open AccessAuxiliary use of ChatGPT in surgical diagnosis and treatment – correspondence
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 13 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4393-4394
Re: ChatGPT encounters multiple opportunities and challenges in neurosurgery
An abstract is unavailable. This article is available as a PDF only.
- 13 September 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (12) , 4393-4394
Open AccessRe: ChatGPT encounters multiple opportunities and challenges in neurosurgery
An abstract is unavailable. This article is available as a PDF only.